IL-17F Protein, Human (HEK293, His)

IL-17F is an inflammatory homodimeric cytokine that induces many proinflammatory cytokines and chemokines. IL-17F also induces antimicrobial peptides. IL-17F plays a protective role in colon cancer development and can be used for the research of autoimmune diseases, infection and cancer^[1][2]. IL-17F Protein, Human (HEK293, His) is a recombinant human IL-17F protein with His tag at the C-terminus and is expressed in HEK293 cells.

Interleukin-17F (IL-17F) belongs to the IL-17 cytokine family. IL-17F is expressed in activated CD4 T cells, activated monocytes, basophils and mast cells. IL-17F can be produced by differentiated TH17 cells, lamina propria T cells, memory CD4⁺ T cells, γδ T cells and NKT cells^[1].
The human IL-17F shares 55.90% amino acid sequence identity with mouse and 57.14% identity with rat.
IL-17F is an inflammatory cytokine that induces many proinflammatory cytokines and chemokines, including TGF-β, IL-2, ICAM1, GM-CSF, CCL2, CCL7, TSLP, MMP13, IL-6 and CXCL1. IL-17F also induces antimicrobial peptides including hBD-2, S100A7, S100A8 and S100A9 with IL-22 and can synergize with IL-23 in human eosinophils to promote the production of IL-1β and IL-6. IL-17F is a homodimeric cytokine. IL-17F shares the most similarities with IL-17A (50% homology) and can be produced as an IL-17AF heterodimer. IL-17A, IL-17F and IL-17A/F use the same receptor complex: IL-17RA and IL-17RC heterodimer. They trigger qualitatively similar signaling pathways, and IL-17F exhibits the lowest biological activity. IL-17F shows about 100–1000 times lower affinity to the IL-17RA subunit than IL-17A, and does not compete with IL-17A binding to IL-17RA^[1][2].
IL-17F plays a protective role in colon cancer development and can be used for the research of autoimmune diseases, infection and cancer^[1][3][4].

IL-17F (50 ng/mL; 16-24 h) induces GRO-α, IL-6, and IL-8 secretion in human primary foreskin fibroblast (BJ) cells^[5].
IL-17F binds weakly to IL-17RA.Fc with an EC₅₀ > 2000 ng/mL, whereas IL-17A binds IL-17RA.Fc with a value of 19 ng/mL, the IL-17F/IL-17A heterodimer has an EC50 of 329 ng/mL^[5].
IL-17F (0-150 ng/mL; 0-72 h) increases the cell viability of PC-3 and DU145^[6].
IL-17F (100 ng/mL; 24 h) stimulates the malignant phenotypes of PCa cells and activates PI3K/AKT signalling pathway in PCa cells^[6].

1.Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 12.46 ng/mL, corresponding to a specific activity is 8.026×10⁴ U/mg.
2. Loaded IL-17F Protein, Human (HEK293, His) on NTA biosensor, can bind Sonelokimab (HY-P99397) with an affinity constant of 2.859E-10 M as determined in BLI assay.

• 
  Measured by its ability to induce IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells.The ED₅₀ for this effect is 12.46 ng/mL, corresponding to a specific activity is 8.026×10⁴ U/mg.
• 
  Loaded IL-17F Protein, Human (HEK293, His) on NTA biosensor, can bind Sonelokimab (HY-P99397) with an affinity constant of 2.859E-10 M as determined in BLI assay.

Human

HEK293

C-6*His

Q96PD4/AAH70124.1 (R31-Q163)

112744  [NCBI]

Full Length of Mature Protein

RKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ

Approximately 19 kDa, based on SDS-PAGE under reducing conditions.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Chang SH, et al. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009 Apr;46(1):7-11.  [Content Brief]

  [2]. McGeachy MJ, et al. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019 Apr 16;50(4):892-906.  [Content Brief]

  [3]. Ferreira N, et al. IL-17A and IL-17F orchestrate macrophages to promote lung cancer. Cell Oncol (Dordr). 2020 Aug;43(4):643-654.  [Content Brief]

  [4]. Tong Z, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7(4):e34959.  [Content Brief]

  [5]. Wright JF, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008 Aug 15;181(4):2799-805.  [Content Brief]

  [6]. Zhu X, et al. IL-17F facilitates prostate cancer cell malignant phenotypes via activation of the PI3K/AKT signalling pathway. Andrologia. 2020 Nov;52(10):e13750.  [Content Brief]